# Study on the Safety of Risperidone on Obese or Overweight Patients With Schizophrenia

> **NCT00511628** · — · TERMINATED · sponsor: **Janssen-Cilag, S.A.** · enrollment: 1717 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder
- Schizophreniform Disorder

## Interventions

- **DRUG:** Risperidone

## Key facts

- **NCT ID:** NCT00511628
- **Lead sponsor:** Janssen-Cilag, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2001-07
- **Primary completion:** —
- **Final completion:** 2003-01
- **Target enrollment:** 1717 (ACTUAL)
- **Why stopped:** Due to the achievement of minimum required sample size and new changes in local regulations.
- **Last updated:** 2011-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00511628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00511628, "Study on the Safety of Risperidone on Obese or Overweight Patients With Schizophrenia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00511628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*